Bevacizumab therapy for glioblastoma: a passionate discussion.
Publication
, Journal Article
Desjardins, A; Friedman, HS
Published in: CNS Oncol
January 2014
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
CNS Oncol
DOI
EISSN
2045-0915
Publication Date
January 2014
Volume
3
Issue
1
Start / End Page
1 / 3
Location
England
Related Subject Headings
- Humans
- Glioblastoma
- Brain Neoplasms
- Bevacizumab
- Antibodies, Monoclonal, Humanized
- Angiogenesis Inhibitors
- 3211 Oncology and carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Desjardins, A., & Friedman, H. S. (2014). Bevacizumab therapy for glioblastoma: a passionate discussion. CNS Oncol, 3(1), 1–3. https://doi.org/10.2217/cns.13.53
Desjardins, Annick, and Henry S. Friedman. “Bevacizumab therapy for glioblastoma: a passionate discussion.” CNS Oncol 3, no. 1 (January 2014): 1–3. https://doi.org/10.2217/cns.13.53.
Desjardins A, Friedman HS. Bevacizumab therapy for glioblastoma: a passionate discussion. CNS Oncol. 2014 Jan;3(1):1–3.
Desjardins, Annick, and Henry S. Friedman. “Bevacizumab therapy for glioblastoma: a passionate discussion.” CNS Oncol, vol. 3, no. 1, Jan. 2014, pp. 1–3. Pubmed, doi:10.2217/cns.13.53.
Desjardins A, Friedman HS. Bevacizumab therapy for glioblastoma: a passionate discussion. CNS Oncol. 2014 Jan;3(1):1–3.
Published In
CNS Oncol
DOI
EISSN
2045-0915
Publication Date
January 2014
Volume
3
Issue
1
Start / End Page
1 / 3
Location
England
Related Subject Headings
- Humans
- Glioblastoma
- Brain Neoplasms
- Bevacizumab
- Antibodies, Monoclonal, Humanized
- Angiogenesis Inhibitors
- 3211 Oncology and carcinogenesis